The treatment landscape for multiple myeloma (MM) continues to evolve as novel immunotherapies move earlier in the disease course, raising questions about the long-standing role of high-dose chemotherapy and autologous stem cell transplant. Results from the phase 2 ImmunoPLANT clinical trial (NCT06376526) presented at the 2025 American society of Hematology (ASH) Annual Meeting indicate that a monoclonal antibody combination involving linvoseltamab (Lynozyfic; Regeneron) may yield significant responses in patients who have traditionally qualified for transplant procedures.
Clearance of residual disease is strongly associated wiht improved progression-free and overall survival in multiple myeloma.2,5
“Based on my experience, I would predict that after having such a good response after such a short time, the disease most likely could stay away for manny years,” he said. “Could it never come back in some patients? I would say its possible.”2
MRD negativity is rapidly proving to be an vital prognostic factor for patients with MM,with increasing interest in using it as an endpoint for clinical research.2 The potential for achieving MRD negativity without undergoing an autotransplant may pave the way for targeting lower-level treatment.
Reconsidering Transplant in the Modern era
Table of Contents
Despite its historical role, autologous stem cell transplant remains a physically demanding intervention.Dr. Landgren emphasized the contrast between transplant and emerging immunotherapies.2
“It’s a quite brutal therapy, wich was first introduced in the U.K.in 1983,” he said, referring to high-dose chemotherapy and transplant.2
As immunotherapeutic regimens begin to express deeper and more profound levels of response earlier, there is increasing debate regarding whether transplant should remain mandatory in all eligible patients or be reserved for relapse situations.4,5
Even though experts suggest that a deeper follow-up is required before modifying clinical practice guidelines, evidence emerging in the immunoPLANT study contributes to a growing body of evidence supporting transplant-sparing approaches in select patients.
Implications for Pharmacists and Clinical Practice
From a pharmaceutical viewpoint, these results confirm the growing role of immunotherapy in MM treatment and underscore the importance of understanding new mechanisms of action, toxicities, and supportive requirements. Bispecific antibodies, including linvoseltamab, require close follow-up for cytokine release syndrome, infections, and hematologic toxicities, all of which are important areas where pharmacists play a significant role.
Dr. Landgren emphasized the aspirational nature of the trial’s goals. “It’s a bold claim,but we need to aim for the stars to move the field forward,” he said. “That is what we are trying to do.”2
As data mature, immunotherapy-driven strategies may redefine frontline myeloma care, offering patients effective disease control with fewer lo
Okay, I will follow your detailed instructions to analyze the provided text and generate a response adhering to all specified constraints.
Provided Text Snippet:
<ol><li><h6><astro-island uid="0" key="0"><span data-testid="external-link" data-title="Bispecific Antibodies in Multiple Myeloma: ASH 2025 Preview" data-plugin=""externallinkplugin"" data-value="true" await-children=""><a href="https://www.cancertherapyadvisor.com/features/bispecific-antibodies-in-multiple-myeloma-ash-2025/" rel="nofollow noreferrer noopener" target="_self">https://www.cancertherapyadvisor.com/features/bispecific-antibodies-in-multiple-myeloma-ash-2025/</a><!--astro:end--></astro-island></h6></li></ol>PHASE 1: ADVERSARIAL RESEARCH, FRESHNESS & BREAKING-NEWS CHECK
The provided link points to an article previewing bispecific antibodies in multiple myeloma at the American society of hematology (ASH) 2025 meeting. As of January 24, 2026, 18:58:32, the ASH 2025 meeting has not yet occurred. The article is a preview and therefore contains anticipated information. I will search for updates on bispecific antibodies in multiple myeloma, focusing on clinical trial results and regulatory approvals since the article’s likely publication date (late 2024/early 2025).
Search Results (as of 2026/01/24 18:58:32):
* Talquetamab (Talvey): Approved by the FDA in August 2023 for relapsed or refractory multiple myeloma.FDA Approval
* Elranatamab (elrexfio): approved by the FDA in November 2023 for relapsed or refractory multiple myeloma. FDA Approval
* Bispecific Antibody Clinical trials: Numerous ongoing clinical trials are evaluating novel bispecific antibodies for multiple myeloma. ClinicalTrials.gov
* Recent ASH 2024 presentations: Presentations at ASH 2024 highlighted promising early data for several bispecific antibodies in combination therapies. Healio – ASH 2024 Coverage
PHASE 2: ENTITY-BASED GEO
* Primary Entity: Bispecific Antibodies in Multiple Myeloma
* Related Entities:
* Multiple Myeloma (Disease)
* American Society of Hematology (ASH) (Professional Organization)
* Food and Drug Administration (FDA) (Regulatory Agency)
* Talquetamab (talvey) (Specific Bispecific Antibody)
* Elranatamab (Elrexfio) (Specific Bispecific Antibody)
* ClinicalTrials.gov (Clinical trial Database)
PHASE 3 & 4: SEMANTIC ANSWER RULE & MACHINE-READABLE FACTS
Bispecific Antibodies in multiple Myeloma
Definition / Direct Answer: Bispecific antibodies are a class of immunotherapy drugs engineered to bind to two different targets simultaneously, and they are showing increasing promise in the treatment of multiple myeloma.
Detail: Multiple myeloma is a cancer of plasma cells, a type of white blood cell. Bispecific antibodies work by binding to a protein on myeloma cells (e.g., BCMA – B-cell maturation antigen) and to a protein on immune cells (e.g., CD3 on T cells), bringing the immune cells into close proximity with the cancer cells to induce their destruction. This approach offers a targeted therapy option, potentially minimizing damage to healthy cells. The field is rapidly evolving with several bispecific antibodies undergoing clinical trials and receiving FDA approval.
Example or Evidence: Talquetamab (Talvey) received FDA approval on august 18, 2023, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. FDA Approval Elranatamab (Elrexfio) received FDA approval on November 16, 2023, for the same patient population. FDA Approval
american Society of Hematology (ASH) and Bispecific Antibody Research
Definition / Direct Answer: The american Society of hematology (ASH)
